Independent pharmacy funding structured by advisors who understand what a PBM reimbursement cycle actually does to your cash flow. RX Fund Assist™ was built for your business, not adapted to it. Our pharmacy advisory team includes licensed pharmacists, not just finance professionals who read about your industry.
Request pharmacy funding
Tell us about your pharmacy. Our PharmD-led team responds within 24 to 48 hours.
"*" indicates required fields
Jonathan Mordis, PharmD, CPh
Partner · VP Business Development
Jason Melachrino, PharmD, MBA, CPh
Partner · VP Pharmacy Services
Member of the National Community Pharmacists Association (NCPA) partner program.
Working Capital
Capital for inventory, payroll, and operations. Structured around script volume and PBM reimbursement cycles.
Pharmacy Line of Credit
Revolving credit for ongoing inventory purchasing. Draws and repays with your actual cash flow.
Equipment Financing
Compounding equipment, automation systems, pharmacy fixtures.
Acquisition Loans
Financing to purchase an existing pharmacy. We underwrite the business, not just the buyer.
Expansion Funding
Capital to open a second pharmacy location. Business plan and projections support available.
Debt Consolidation
Consolidate multiple vendor obligations (Cardinal, McKesson, Anda) into one structured payment.
Independent pharmacies operate on a cash flow model that most lenders, and most banks, have never had to understand. The timing gap between when a pharmacy dispenses a prescription and when it receives reimbursement from a PBM (pharmacy benefit manager) can stretch 14 to 45 days. During that window, the pharmacy has already paid the drug cost to its wholesaler. That float, multiplied across thousands of prescriptions and dozens of payers, creates a structural working capital gap that has nothing to do with credit quality and everything to do with how the reimbursement system is designed.
Direct and Indirect Remuneration fees are retroactive clawbacks applied by PBMs, sometimes months after a prescription is dispensed, that reduce the net reimbursement the pharmacy actually receives. Because DIR fees are assessed after the fact, a pharmacy cannot accurately forecast its net revenue in real time. For independent pharmacies without the cash reserves of a large chain, an unexpected DIR reconciliation period can create an immediate liquidity crisis that looks, on paper, like a poorly run business. It is not. It is a cash timing problem created by a payment system the pharmacy has no control over.
Pharmacies participating in the 340B drug discount program purchase medications at a reduced cost, but the billing, compliance, and audit requirements create administrative overhead that traditional lenders do not factor into their underwriting. A 340B-eligible pharmacy may show lower drug costs on its income statement while carrying higher operational complexity, a trade-off a standard credit model will misread as weakness.
Wholesalers like Cardinal Health, McKesson, and Cencora (formerly AmerisourceBergen) extend net-7 to net-14 payment terms to independent pharmacies. When a pharmacy’s PBM reimbursements are delayed or clawed back, those distributor invoices come due before the receivables arrive. The result is a cash flow cycle that forces pharmacies to choose between maintaining adequate inventory and staying current with their primary supplier, a choice no well-run pharmacy should have to make.
CCD’s pharmacy funding team, which includes licensed pharmacists who have operated in these environments, underwrites pharmacy businesses against these real operational metrics: script volume, payer mix, PBM reimbursement rate, DIR exposure, and distributor payment cycle. We do not run your pharmacy through a generic small business loan model. We evaluate it the way someone who has stood behind a dispensing counter would.
Start with a call or our online application. Our PharmD-led team reviews your pharmacy’s financials, script volume, and funding needs, then presents customized options within 24–48 hours. We evaluate pharmacy businesses using industry-specific criteria, not generic credit box scoring.
Frequently, yes. Banks often decline pharmacy loans because their underwriters don’t understand pharmacy-specific metrics, PBM reimbursement timing, 340B program dynamics, distributor payment structures. Our team evaluates pharmacies using those exact criteria. We regularly fund pharmacies that conventional lenders have turned away.
Yes. RX Fund Assist™ provides startup funding for new pharmacy locations including working capital, equipment financing, and build-out costs. Our advisory team can also assist with business planning and financial projections for the startup phase.
Initial review requires minimal documentation, typically 3–6 months of business bank statements, a completed application, and a current script count report. For larger or acquisition financing, we will also request tax returns and a business plan. Our team walks you through exactly what’s needed.
PharmD-led team. Decisions in 24 to 48 hours.
Single-source capital advisory since 2003.
10101 W Sample Rd
Coral Springs, FL 33065
Resources
